{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} Pre-Surgical Chemotherapy in early-Stage Pancreatic Cancer
Activity Steps
{{ evaluation.question.text }}
{{choice.text}}
{{evaluation.answerSet[0].text}}
Learning Objectives
After completing this continuing education activity you will be able to:
- Evaluate the patient enrollment, drug regimens used, and results from the Phase 2 S1505 trial.
- Identify staging criteria and survival rates for patients with pancreatic cancer.
Disclosures
The author(s), faculty, staff, and planners in any position to control the content of this activity, have disclosed that they have no financial relationships with, or financial interests in, any commercial companies relevant to this educational activity.
Price:
$12.95
Credits:
- ANCC 1.0 CH
- DC - BON 1.0 CH
- FL - BON 1.0 CH
- GA - BON 1.0 CH
Lippincott Professional Development is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. This activity is also provider approved by the California Board of Registered Nursing, Provider Number CEP 11749. Lippincott Professional Development is also an approved provider of continuing nursing education by the District of Columbia Board of Nursing, Florida Board of Nursing, and Georgia Board of Nursing, #50-1223.
{{ evaluation.question.text }}
{{choice.text}}
{{evaluation.answerSet[0].text}}
Test Code: OT0521
Published: May 2021
Expires: 3/7/2025
Sources:
Oncology Times
Required Passing Score: 8/10 (80%)
Specialties:
Oncology